Radiopharm Receives Positive Recommendation to Increase Dose Level in Phase One Dose Escalating Cancer Clinical Trial, Shares Up 5%

MT Newswires Live

04/08

Radiopharm Theranostics (ASX:RAD) received a positive recommendation from the data safety and monitoring committee to progress its clinical-stage radiotherapeutic candidate, lutetium-177-RAD202, to the next dose level of 130 millicurie (mCi) from 75 mCi in the phase one "HEAT" dose escalating clinical trial in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors, according to a Wednesday Australian bourse filing.

The favorable safety profile allows the firm to accelerate the dose escalation from the second group to the third group, the firm's Chief Executive, Riccardo Canevari, said.

Its shares rose 5% in recent trading on Wednesday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2625990372"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2625990372\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2625990372?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-08 14:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625990372","market":"sg","top_or_hot":-1,"title":"Radiopharm Receives Positive Recommendation to Increase Dose Level in Phase One Dose Escalating Cancer Clinical Trial, Shares Up 5%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/RDPTF\">Radiopharm Theranostics</a> (ASX:RAD) received a positive recommendation from the data safety and monitoring committee to progress its clinical-stage radiotherapeutic candidate, lutetium-177-RAD202, to the next dose level of 130 millicurie (mCi) from 75 mCi in the phase one \"HEAT\" dose escalating clinical trial in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors, according to a Wednesday Australian bourse filing.</p><p>The favorable safety profile allows the firm to accelerate the dose escalation from the second group to the third group, the firm's Chief Executive, Riccardo Canevari, said.</p><p>Its shares rose 5% in recent trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Radiopharm Receives Positive Recommendation to Increase Dose Level in Phase One Dose Escalating Cancer Clinical Trial, Shares Up 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRadiopharm Receives Positive Recommendation to Increase Dose Level in Phase One Dose Escalating Cancer Clinical Trial, Shares Up 5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-08 14:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/RDPTF\">Radiopharm Theranostics</a> (ASX:RAD) received a positive recommendation from the data safety and monitoring committee to progress its clinical-stage radiotherapeutic candidate, lutetium-177-RAD202, to the next dose level of 130 millicurie (mCi) from 75 mCi in the phase one \"HEAT\" dose escalating clinical trial in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors, according to a Wednesday Australian bourse filing.</p><p>The favorable safety profile allows the firm to accelerate the dose escalation from the second group to the third group, the firm's Chief Executive, Riccardo Canevari, said.</p><p>Its shares rose 5% in recent trading on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RAD.AU","symbol_name":"RADIOPHARM THERANOSTICS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2625990372","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2625990372","pubTimestamp":1775629155,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Radiopharm Theranostics  received a positive recommendation from the data safety and monitoring committee to progress its clinical-stage radiotherapeutic candidate, lutetium-177-RAD202, to the next dose level of 130 millicurie  from 75 mCi in the phase one \"HEAT\" dose escalating clinical trial in patients with Human Epidermal Growth Factor Receptor 2 -positive advanced solid tumors, according to a Wednesday Australian bourse filing.The favorable safety profile allows the firm to accelerate the dose escalation from the second group to the third group, the firm's Chief Executive, Riccardo Canevari, said.Its shares rose 5% in recent trading on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RAD.AU":"RADIOPHARM THERANOSTICS LTD","BK7067":"生物科技"},"translate_title":"Radiopharm在第一阶段剂量递增癌症临床试验中获得增加剂量水平的积极建议，股价上涨5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAD.AU":1},"content_text":"Radiopharm Theranostics (ASX:RAD) received a positive recommendation from the data safety and monitoring committee to progress its clinical-stage radiotherapeutic candidate, lutetium-177-RAD202, to the next dose level of 130 millicurie (mCi) from 75 mCi in the phase one \"HEAT\" dose escalating clinical trial in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors, according to a Wednesday Australian bourse filing.The favorable safety profile allows the firm to accelerate the dose escalation from the second group to the third group, the firm's Chief Executive, Riccardo Canevari, said.Its shares rose 5% in recent trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}